ZA200507562B - HIV-peptide-carrier-conjugates - Google Patents

HIV-peptide-carrier-conjugates Download PDF

Info

Publication number: ZA200507562B
Authority: ZA; South Africa
Prior art keywords: composition; seq; amino acid; virus; acid sequence
Prior art date: 2003-03-26

Application number

ZA200507562A

Other languages

English (en)

Inventor

Martin F Bachmann

Huber Adrian

Manolova Vania

Meijerink Edwin

Karl G Proba

Tissot Alain

Original Assignee

Cytos Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-26

Filing date

2004-03-25

Publication date

2006-11-29

2004-03-25 Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag

2006-11-29 Publication of ZA200507562B publication Critical patent/ZA200507562B/en

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 281
102000004196 processed proteins & peptides Human genes 0.000 claims description 232
239000000203 mixture Substances 0.000 claims description 230
229920001184 polypeptide Polymers 0.000 claims description 223
239000000427 antigen Substances 0.000 claims description 222
108091007433 antigens Proteins 0.000 claims description 214
102000036639 antigens Human genes 0.000 claims description 214
101710132601 Capsid protein Proteins 0.000 claims description 205
239000002245 particle Substances 0.000 claims description 192
108091034117 Oligonucleotide Proteins 0.000 claims description 150
230000003308 immunostimulating effect Effects 0.000 claims description 132
101710125418 Major capsid protein Proteins 0.000 claims description 123
125000003275 alpha amino acid group Chemical group 0.000 claims description 111
108090000623 proteins and genes Proteins 0.000 claims description 105
239000000126 substance Substances 0.000 claims description 104
102000004169 proteins and genes Human genes 0.000 claims description 85
235000018102 proteins Nutrition 0.000 claims description 84
150000007523 nucleic acids Chemical class 0.000 claims description 83
238000000034 method Methods 0.000 claims description 82
229960005486 vaccine Drugs 0.000 claims description 80
230000000890 antigenic effect Effects 0.000 claims description 79
102000039446 nucleic acids Human genes 0.000 claims description 71
108020004707 nucleic acids Proteins 0.000 claims description 71
108020004414 DNA Proteins 0.000 claims description 62
230000028993 immune response Effects 0.000 claims description 60
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 58
241000829111 Human polyomavirus 1 Species 0.000 claims description 53
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 53
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 52
241001465754 Metazoa Species 0.000 claims description 52
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 52
239000012634 fragment Substances 0.000 claims description 47
241000700605 Viruses Species 0.000 claims description 44
230000027455 binding Effects 0.000 claims description 43
108091081548 Palindromic sequence Proteins 0.000 claims description 42
210000004027 cell Anatomy 0.000 claims description 42
241001515965 unidentified phage Species 0.000 claims description 39
239000002773 nucleotide Substances 0.000 claims description 38
125000003729 nucleotide group Chemical group 0.000 claims description 38
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 36
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 36
102000002067 Protein Subunits Human genes 0.000 claims description 31
230000004048 modification Effects 0.000 claims description 31
238000012986 modification Methods 0.000 claims description 31
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 31
230000005867 T cell response Effects 0.000 claims description 30
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 30
108010001267 Protein Subunits Proteins 0.000 claims description 28
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 26
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 26
241000282414 Homo sapiens Species 0.000 claims description 26
239000002671 adjuvant Substances 0.000 claims description 26
229940029575 guanosine Drugs 0.000 claims description 26
230000003612 virological effect Effects 0.000 claims description 25
230000002708 enhancing effect Effects 0.000 claims description 23
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 22
239000013612 plasmid Substances 0.000 claims description 22
108091035707 Consensus sequence Proteins 0.000 claims description 21
230000003252 repetitive effect Effects 0.000 claims description 21
230000003053 immunization Effects 0.000 claims description 19
241000700721 Hepatitis B virus Species 0.000 claims description 18
108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
102000004895 Lipoproteins Human genes 0.000 claims description 12
108090001030 Lipoproteins Proteins 0.000 claims description 12
210000003719 b-lymphocyte Anatomy 0.000 claims description 12
230000036755 cellular response Effects 0.000 claims description 12
241000124008 Mammalia Species 0.000 claims description 11
229920002477 rna polymer Polymers 0.000 claims description 10
125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
230000004044 response Effects 0.000 claims description 9
102000053602 DNA Human genes 0.000 claims description 8
101710177291 Gag polyprotein Proteins 0.000 claims description 8
102000002689 Toll-like receptor Human genes 0.000 claims description 8
108020000411 Toll-like receptor Proteins 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 8
229940031689 heterologous vaccine Drugs 0.000 claims description 8
230000001939 inductive effect Effects 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
102000004127 Cytokines Human genes 0.000 claims description 7
108090000695 Cytokines Proteins 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 7
101710192141 Protein Nef Proteins 0.000 claims description 7
108010015780 Viral Core Proteins Proteins 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
241000709738 Enterobacteria phage fr Species 0.000 claims description 6
241000702670 Rotavirus Species 0.000 claims description 6
241001672158 Acinetobacter phage AP205 Species 0.000 claims description 5
101710197658 Capsid protein VP1 Proteins 0.000 claims description 5
229940021995 DNA vaccine Drugs 0.000 claims description 5
241000709737 Enterobacteria phage GA Species 0.000 claims description 5
241000709747 Enterobacteria phage R17 Species 0.000 claims description 5
241000709743 Enterobacteria phage SP Species 0.000 claims description 5
241000709744 Enterobacterio phage MS2 Species 0.000 claims description 5
241000712079 Measles morbillivirus Species 0.000 claims description 5
241000714209 Norwalk virus Species 0.000 claims description 5
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 5
101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 5
101710108545 Viral protein 1 Proteins 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
210000001165 lymph node Anatomy 0.000 claims description 5
230000037452 priming Effects 0.000 claims description 5
241001430294 unidentified retrovirus Species 0.000 claims description 5
108010041986 DNA Vaccines Proteins 0.000 claims description 4
241001261579 Enterobacteria phage M11 Species 0.000 claims description 4
241001278075 Enterobacteria phage MX1 Species 0.000 claims description 4
241000710198 Foot-and-mouth disease virus Species 0.000 claims description 4
241000701806 Human papillomavirus Species 0.000 claims description 4
108091005804 Peptidases Proteins 0.000 claims description 4
241000709749 Pseudomonas phage PP7 Species 0.000 claims description 4
241000710960 Sindbis virus Species 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
230000003213 activating effect Effects 0.000 claims description 4
239000002158 endotoxin Substances 0.000 claims description 4
229920006008 lipopolysaccharide Polymers 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
239000004365 Protease Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
108010061833 Integrases Proteins 0.000 claims description 2
230000028327 secretion Effects 0.000 claims description 2
102100034343 Integrase Human genes 0.000 claims 3
230000000063 preceeding effect Effects 0.000 claims 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 description 185
CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 117
101710094648 Coat protein Proteins 0.000 description 113
101710141454 Nucleoprotein Proteins 0.000 description 113
101710083689 Probable capsid protein Proteins 0.000 description 113
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 109
235000001014 amino acid Nutrition 0.000 description 88
229940024606 amino acid Drugs 0.000 description 88
108091032973 (ribonucleotides)n+m Proteins 0.000 description 75
210000000234 capsid Anatomy 0.000 description 75
150000001413 amino acids Chemical class 0.000 description 58
238000005859 coupling reaction Methods 0.000 description 48
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 45
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 41
102000005891 Pancreatic ribonuclease Human genes 0.000 description 41
230000008878 coupling Effects 0.000 description 38
238000010168 coupling process Methods 0.000 description 38
230000004927 fusion Effects 0.000 description 30
239000013256 coordination polymer Substances 0.000 description 27
102000037865 fusion proteins Human genes 0.000 description 26
108020001507 fusion proteins Proteins 0.000 description 26
239000004971 Cross linker Substances 0.000 description 24
239000000499 gel Substances 0.000 description 23
238000003780 insertion Methods 0.000 description 22
230000037431 insertion Effects 0.000 description 22
125000000539 amino acid group Chemical group 0.000 description 21
238000011282 treatment Methods 0.000 description 21
210000004899 c-terminal region Anatomy 0.000 description 19
239000013598 vector Substances 0.000 description 19
208000015181 infectious disease Diseases 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 17
241000588724 Escherichia coli Species 0.000 description 16
238000000502 dialysis Methods 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
238000007792 addition Methods 0.000 description 15
238000012217 deletion Methods 0.000 description 15
230000037430 deletion Effects 0.000 description 15
229960005542 ethidium bromide Drugs 0.000 description 15
208000002672 hepatitis B Diseases 0.000 description 15
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
210000004443 dendritic cell Anatomy 0.000 description 14
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 14
238000002649 immunization Methods 0.000 description 14
230000002163 immunogen Effects 0.000 description 14
238000006467 substitution reaction Methods 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
230000029087 digestion Effects 0.000 description 13
238000011534 incubation Methods 0.000 description 13
239000003446 ligand Substances 0.000 description 13
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 12
239000011543 agarose gel Substances 0.000 description 12
235000018417 cysteine Nutrition 0.000 description 12
239000000178 monomer Substances 0.000 description 12
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
230000003993 interaction Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
108090000565 Capsid Proteins Proteins 0.000 description 10
102100023321 Ceruloplasmin Human genes 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
239000007771 core particle Substances 0.000 description 10
230000005012 migration Effects 0.000 description 10
238000013508 migration Methods 0.000 description 10
238000004806 packaging method and process Methods 0.000 description 10
239000002243 precursor Substances 0.000 description 10
238000002255 vaccination Methods 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
108010076039 Polyproteins Proteins 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000013459 approach Methods 0.000 description 9
238000003491 array Methods 0.000 description 9
230000002458 infectious effect Effects 0.000 description 9
238000000746 purification Methods 0.000 description 9
102100024065 Inhibitor of growth protein 1 Human genes 0.000 description 8
101710107921 Secreted protein BARF1 Proteins 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000002523 gelfiltration Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
239000004471 Glycine Substances 0.000 description 7
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 7
241001505332 Polyomavirus sp. Species 0.000 description 7
108010034546 Serratia marcescens nuclease Proteins 0.000 description 7
230000004913 activation Effects 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000004202 carbamide Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000001493 electron microscopy Methods 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
-1 phosphoester Chemical class 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
230000003362 replicative effect Effects 0.000 description 7
241000701447 unidentified baculovirus Species 0.000 description 7
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
108010083644 Ribonucleases Proteins 0.000 description 6
102000006382 Ribonucleases Human genes 0.000 description 6
108091008874 T cell receptors Proteins 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
210000000612 antigen-presenting cell Anatomy 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
238000001212 derivatisation Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
230000006870 function Effects 0.000 description 6
229930182817 methionine Natural products 0.000 description 6
238000012545 processing Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
238000001338 self-assembly Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
241000894007 species Species 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
241000388186 Deltapapillomavirus 4 Species 0.000 description 5
241000282412 Homo Species 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
102100034349 Integrase Human genes 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
235000009697 arginine Nutrition 0.000 description 5
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
230000008901 benefit Effects 0.000 description 5
238000010367 cloning Methods 0.000 description 5
239000013078 crystal Substances 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
125000000524 functional group Chemical group 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
239000012160 loading buffer Substances 0.000 description 5
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
244000005700 microbiome Species 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010186 staining Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 4
MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 4
101800001318 Capsid protein VP4 Proteins 0.000 description 4
208000035473 Communicable disease Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108010067770 Endopeptidase K Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
238000000246 agarose gel electrophoresis Methods 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000028996 humoral immune response Effects 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
229930000044 secondary metabolite Natural products 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
241000271566 Aves Species 0.000 description 3
108020000946 Bacterial DNA Proteins 0.000 description 3
101150083464 CP gene Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241001278054 Enterobacteria phage NL95 Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000005007 innate immune system Anatomy 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
230000035800 maturation Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
229940046166 oligodeoxynucleotide Drugs 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
239000012474 protein marker Substances 0.000 description 3
210000003705 ribosome Anatomy 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229920001059 synthetic polymer Polymers 0.000 description 3
230000014616 translation Effects 0.000 description 3
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
238000005199 ultracentrifugation Methods 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
238000011510 Elispot assay Methods 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108010040721 Flagellin Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
241001631646 Papillomaviridae Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
241000125945 Protoparvovirus Species 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
229940029030 dendritic cell vaccine Drugs 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
239000000539 dimer Substances 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
229960002143 fluorescein Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
239000010931 gold Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
150000003949 imides Chemical class 0.000 description 2
230000000951 immunodiffusion Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000006166 lysate Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000013365 molecular weight analysis method Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000006384 oligomerization reaction Methods 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
229940023041 peptide vaccine Drugs 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000004713 phosphodiesters Chemical group 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000012743 protein tagging Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
229960003471 retinol Drugs 0.000 description 2
235000020944 retinol Nutrition 0.000 description 2
239000011607 retinol Substances 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
238000007086 side reaction Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
GNTFNWAZTKLCRE-UHFFFAOYSA-N 4-amino-4-bromo-1,3-dihydropyrimidin-2-one Chemical compound NC1(Br)NC(=O)NC=C1 GNTFNWAZTKLCRE-UHFFFAOYSA-N 0.000 description 1
OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
101150035093 AMPD gene Proteins 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241000701242 Adenoviridae Species 0.000 description 1
241000701386 African swine fever virus Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
241000239223 Arachnida Species 0.000 description 1
241000712892 Arenaviridae Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000702628 Birnaviridae Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
241000282836 Camelus dromedarius Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710169873 Capsid protein G8P Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241001275954 Cortinarius caperatus Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000723655 Cowpea mosaic virus Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
208000021075 Creatine deficiency syndrome Diseases 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
241000710829 Dengue virus group Species 0.000 description 1
241001115402 Ebolavirus Species 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000709739 Enterobacteria phage f2 Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
101710142246 External core antigen Proteins 0.000 description 1
206010063827 Extramedullary haemopoiesis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
241000711950 Filoviridae Species 0.000 description 1
241000723754 Flock house virus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
241001506229 Goose reovirus Species 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
229940033330 HIV vaccine Drugs 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
241000150562 Hantaan orthohantavirus Species 0.000 description 1
102100021410 Heat shock 70 kDa protein 14 Human genes 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000700739 Hepadnaviridae Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
241000700586 Herpesviridae Species 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
101001041756 Homo sapiens Heat shock 70 kDa protein 14 Proteins 0.000 description 1
101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000701828 Human papillomavirus type 11 Species 0.000 description 1
241000341655 Human papillomavirus type 16 Species 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
241000701377 Iridoviridae Species 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
241000701646 Kappapapillomavirus 2 Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
101710135729 Major capsid protein L1 Proteins 0.000 description 1
101710156564 Major tail protein Gp23 Proteins 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108091060545 Nonsense suppressor Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000712464 Orthomyxoviridae Species 0.000 description 1
241000150218 Orthonairovirus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000711504 Paramyxoviridae Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000713137 Phlebovirus Species 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000700625 Poxviridae Species 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000702247 Reoviridae Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
RKEITGVZZHXKON-SKAWGCAZSA-N Thymidine glycol Chemical compound O=C1NC(=O)C(C)(O)C(O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 RKEITGVZZHXKON-SKAWGCAZSA-N 0.000 description 1
241000710924 Togaviridae Species 0.000 description 1
102100027010 Toll-like receptor 1 Human genes 0.000 description 1
102100027009 Toll-like receptor 10 Human genes 0.000 description 1
102100024333 Toll-like receptor 2 Human genes 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
102100039387 Toll-like receptor 6 Human genes 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000120645 Yellow fever virus group Species 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
108700010877 adenoviridae proteins Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
101150115889 al gene Proteins 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000309743 astrovirus Species 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
229950009494 bropirimine Drugs 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
201000008609 cerebral creatine deficiency syndrome Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
230000008029 eradication Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000013265 extended release Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
208000029570 hepatitis D virus infection Diseases 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
235000013902 inosinic acid Nutrition 0.000 description 1
229940028843 inosinic acid Drugs 0.000 description 1
239000004245 inosinic acid Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000001911 interdigitating cell Anatomy 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229950005634 loxoribine Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960003151 mercaptamine Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
239000013586 microbial product Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000005580 one pot reaction Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
108010094020 polyglycine Proteins 0.000 description 1
229920000232 polyglycine polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
108010000222 polyserine Proteins 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
238000011809 primate model Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
238000000527 sonication Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
229940043517 specific immunoglobulins Drugs 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009258 tissue cross reactivity Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
241000724775 unclassified viruses Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
229940023147 viral vector vaccine Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ZA200507562A 2003-03-26 2004-03-25 HIV-peptide-carrier-conjugates ZA200507562B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45734803P	2003-03-26	2003-03-26

Publications (1)

Publication Number	Publication Date
ZA200507562B true ZA200507562B (en)	2006-11-29

Family

ID=33098221

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ZA200507063A ZA200507063B (en)	2003-03-26	2004-03-25	Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
ZA200507562A ZA200507562B (en)	2003-03-26	2004-03-25	HIV-peptide-carrier-conjugates
ZA200506541A ZA200506541B (en)	2003-03-26	2005-08-16	Melan-A peptide analogue-virus-like-particle conjugates

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ZA200507063A ZA200507063B (en)	2003-03-26	2004-03-25	Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200506541A ZA200506541B (en)	2003-03-26	2005-08-16	Melan-A peptide analogue-virus-like-particle conjugates

Country Status (13)

Country	Link
US (2)	US7517520B2 (ru)
EP (3)	EP1606398A1 (ru)
JP (1)	JP5022028B2 (ru)
KR (1)	KR20050115913A (ru)
CN (2)	CN100560719C (ru)
AU (3)	AU2004224761A1 (ru)
BR (1)	BRPI0408623A (ru)
CA (3)	CA2519165A1 (ru)
MX (1)	MXPA05009289A (ru)
NZ (1)	NZ542323A (ru)
RU (1)	RU2351362C2 (ru)
WO (3)	WO2004084940A1 (ru)
ZA (3)	ZA200507063B (ru)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US7320793B2 (en) *	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
EP2196217A1 (en)	2001-09-14	2010-06-16	Cytos Biotechnology AG	Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
ATE489969T1 (de) *	2002-06-20	2010-12-15	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2004007538A2 (en) *	2002-07-17	2004-01-22	Cytos Biotechnology Ag	Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
DK1524994T3 (da) *	2002-07-19	2011-08-15	Cytos Biotechnology Ag	Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
CN101948835A (zh)	2002-10-29	2011-01-19	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CN100560719C (zh) *	2003-03-26	2009-11-18	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en) *	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
US9090673B2 (en)	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
AU2005274649B2 (en)	2004-08-19	2010-09-09	University College Cardiff Consultants Limited	Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy
KR20070059207A (ko) *	2004-10-05	2007-06-11	사이토스 바이오테크놀로지 아게	Ｖｌｐ-항원 컨쥬게이트 및 백신으로서 그의 용도
KR100721928B1 (ko) *	2004-11-05	2007-05-28	주식회사 바이오씨에스	ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US20080003232A1 (en) *	2004-11-29	2008-01-03	Liying Wang	Cpg Single Strand Deoxynucleotides for Use as Adjuvant
US20090068224A1 (en) *	2005-01-31	2009-03-12	Vaxinnate Corporation	Method to identify polypeptide toll-like receptor (tlr) ligands
NZ561040A (en) *	2005-03-18	2009-04-30	Cytos Biotechnology Ag	Cat allergen fusion proteins and use thereof
US20110008831A1 (en) *	2005-05-26	2011-01-13	Cytos Biotechnology Ag	Scalable fermentation process
EP1896068A1 (en) *	2005-06-14	2008-03-12	Cytos Biotechnology AG	Antigen conjugates and uses thereof
WO2006138568A2 (en) *	2005-06-17	2006-12-28	Mannkind Corporation	Multivalent entrain-and-amplify immunotherapeutics for carcinoma
EP1736538A1 (en) *	2005-06-21	2006-12-27	Cytos Biotechnology AG	Process for the preparative purification of virus-like-particles (VLPs)
FR2887457B1 (fr)	2005-06-23	2007-10-05	Fond Bettencourt Schueller	Vaccination par ciblage transcutane
CA2612162C (en) *	2005-07-01	2016-05-17	Index Pharmaceuticals Ab	Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
SI2179737T1 (sl)	2005-07-01	2014-02-28	Index Pharmaceuticals Ab	Modulacija reakcije na stereoide
US7468186B2 (en) *	2005-07-22	2008-12-23	City Of Hope	Polyomavirus cellular epitopes and uses therefor
US8338173B2 (en) *	2005-08-11	2012-12-25	University College Cardiff Consultants Limited	Preparation of antigen-presenting human γδ T cells and use in immunotherapy
BRPI0504117A (pt) *	2005-09-05	2007-05-22	Fundacao De Amparo A Pesquisa	epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
WO2007039458A2 (en) *	2005-09-21	2007-04-12	Cytos Biotechnology Ag	Hiv peptide conjugates and uses thereof
AU2006306805A1 (en) *	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US20080044438A1 (en) *	2006-03-17	2008-02-21	Ostroff Gary R	Yeast Cell Particles As Oral Delivery Vehicles For Antigens
KR101552227B1 (ko)	2006-06-12	2015-09-10	사이토스 바이오테크놀로지 아게	올리고뉴클레오티드를 ｒｎａ 박테리오파지의 바이러스-유사 입자로 패키징하는 방법
AU2013204383B2 (en) *	2006-06-12	2016-09-22	Kuros Us Llc	Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US9803189B2 (en)	2006-08-23	2017-10-31	Stc.Unm	Virus-like platform for rapid vaccine discovery
AU2007333147B2 (en)	2006-12-12	2013-12-19	Kuros Us Llc	Oligonucleotides containing high concentrations of guanine monomers
WO2008071774A1 (en) *	2006-12-14	2008-06-19	Cytos Biotechnology Ag	Purification process for coat protein of rna bacteriophages
LT3056214T (lt)	2008-06-27	2019-06-10	Zoetis Services Llc	Naujos adjuvantų kompozicijos
CA2744987C (en)	2008-12-02	2018-01-16	Chiralgen, Ltd.	Method for the synthesis of phosphorus atom modified nucleic acids
MX337723B (es) *	2008-12-09	2016-03-15	Pfizer Vaccines Llc	Vacuna de peptido ch3 de ige.
WO2010122164A1 (en)	2009-04-23	2010-10-28	Cytos Biotechnology Ag	VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
WO2010138193A2 (en)	2009-05-27	2010-12-02	Selecta Biosciences, Inc.	Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US8431530B2 (en) *	2009-06-12	2013-04-30	Morehouse School Of Medicine	Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
CA2767253A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc.	Novel nucleic acid prodrugs and methods of use thereof
DE102009034779A1 (de)	2009-07-25	2011-02-03	Emc Microcollections Gmbh	Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
CA3030893C (en)	2009-11-02	2022-11-29	The Trustees Of The University Of Pennsylvania	Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2011109422A2 (en)	2010-03-02	2011-09-09	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
EP2547695B1 (en)	2010-03-16	2018-05-09	Biontech Protein Therapeutics GmbH	Tumor vaccination involving a humoral immune response against self-protein cldn18.2
EP2366709A1 (en) *	2010-03-16	2011-09-21	BioNTech AG	Tumor vaccination involving a humoral immune response against self-proteins
WO2011150264A2 (en)	2010-05-26	2011-12-01	Selecta Biosciences, Inc.	Synthetic nanocarrier combination vaccines
EP2407534A1 (en)	2010-07-14	2012-01-18	Neo Virnatech, S.L.	Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
WO2012037078A2 (en) *	2010-09-14	2012-03-22	Stc.Unm	Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
WO2012061717A1 (en)	2010-11-05	2012-05-10	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
RU2442604C1 (ru) *	2010-12-09	2012-02-20	Иосиф Григорьевич Атабеков	Способ усиления иммунного ответа
RU2441667C1 (ru) *	2010-12-09	2012-02-10	Иосиф Григорьевич Атабеков	Новый тип частиц-носителей (платформ) для получения активных комплексов
RU2440140C1 (ru) *	2010-12-09	2012-01-20	Иосиф Григорьевич Атабеков	Иммуногенная композиция, содержащая чужеродные антигены на поверхности сферических носителей, полученных при термической денатурации спиральных вирусов
GB201021867D0 (en) *	2010-12-23	2011-02-02	Mologen Ag	Non-coding immunomodulatory DNA construct
MX373641B (es)	2011-04-29	2020-05-04	Selecta Biosciences Inc	Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
WO2013012758A1 (en)	2011-07-19	2013-01-24	Ontorii, Inc.	Methods for the synthesis of functionalized nucleic acids
CA2843274A1 (en)	2011-07-29	2013-02-07	Selecta Biosciences, Inc.	Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
CN102336821B (zh) *	2011-08-11	2014-10-15	北京永泰免疫应用科技有限公司	Melan-A表位肽及其在预防和/或治疗肿瘤中的用途
CN109182266A (zh) *	2011-12-12	2019-01-11	细胞药物有限公司	扩大t细胞的方法
BR112014013035A2 (pt)	2011-12-22	2018-10-09	Hoffmann La Roche	métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
RU2485973C1 (ru)	2012-02-28	2013-06-27	Общество с ограниченной ответственностью "НТфарма"	Рекомбинантная трехвалентная вакцина от гриппа человека
US9296792B2 (en)	2012-05-23	2016-03-29	The Board Of Trustees Of The Leland Stanford Junior University	Ordered flagellin array as an immunostimulant
JP6268157B2 (ja)	2012-07-13	2018-01-24	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	不斉補助基
KR102712879B1 (ko)	2012-07-13	2024-10-04	웨이브 라이프 사이언시스 리미티드	키랄 제어
CN104684923B (zh)	2012-07-13	2018-09-28	株式会社新日本科学	手性核酸佐剂
JP2016507520A (ja)	2013-01-23	2016-03-10	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	安定化されたｂ型肝炎コアポリペプチド
WO2014145205A2 (en)	2013-03-15	2014-09-18	St. Jude Children's Research Hospital	Methods and compositions of p27kip1 transcription modulators
EP2968519B1 (en)	2013-03-15	2020-05-06	The Trustees Of The University Of Pennsylvania	Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
CN105283175A (zh)	2013-05-03	2016-01-27	西莱克塔生物科技公司	用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
EA201592273A1 (ru)	2013-06-04	2016-09-30	Селекта Байосайенсиз, Инк.	Повторное введение неиммуносупрессивных антигенспецифических иммунотерапевтических средств
WO2015042369A2 (en)	2013-09-19	2015-03-26	Zoetis Llc	Oil-based adjuvants
AU2014324535B2 (en)	2013-09-29	2017-03-30	St. Jude Children's Research Hospital, Inc.	Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
JP2017500313A (ja) *	2013-12-09	2017-01-05	ブレットバイオテクノロジー，インコーポレーテッドＢｕｌｌｅｔＢｉｏｔｅｃｈｎｏｌｏｇｙ，Ｉｎｃ．	特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用
CN104761644A (zh) *	2014-01-03	2015-07-08	百奇生物科技（苏州）有限公司	大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP4137572A1 (en)	2014-01-16	2023-02-22	Wave Life Sciences Ltd.	Chiral design
GB2523187A (en) *	2014-02-18	2015-08-19	Mologen Ag	Covalently closed non-coding immunomodulatory DNA construct
WO2015200728A1 (en)	2014-06-25	2015-12-30	Selecta Biosciences, Inc.	Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
KR20170045344A (ko)	2014-09-07	2017-04-26	셀렉타 바이오사이언시즈, 인크.	항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
JP6715775B2 (ja) *	2014-12-25	2020-07-01	国立研究開発法人医薬基盤・健康・栄養研究所	非凝集性免疫賦活化オリゴヌクレオチド
EP3240801B1 (en)	2014-12-31	2021-01-20	Checkmate Pharmaceuticals, Inc.	Combination tumor immunotherapy
AU2016207099C1 (en)	2015-01-15	2021-02-04	University Of Copenhagen	Virus-like particle with efficient epitope display
DK3244920T5 (da) *	2015-01-16	2024-10-07	Zoetis Services Llc	Mund- og klovsyge-vaccine
EP3786164B1 (en)	2015-06-18	2024-08-14	Ting Therapeutics LLC	Methods and compositions for the prevention and treatment of hearing loss
LU92821B1 (en)	2015-09-09	2017-03-20	Mologen Ag	Combination comprising immunostimulatory oligonucleotides
EP3347044B1 (en) *	2015-09-10	2023-04-19	Academia Sinica	Bird flu vaccine combination comprising virus-like particles and novel adjuvants
GB2542425A (en)	2015-09-21	2017-03-22	Mologen Ag	Means for the treatment of HIV
DK3368068T3 (da)	2015-10-30	2021-02-22	Univ Copenhagen	Viruslignende partikler med effektiv epitopdisplay
US20170157215A1 (en)	2015-12-04	2017-06-08	Jomoco, Corp.	Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US20190046638A1 (en)	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
DK3448364T3 (da)	2016-04-29	2022-05-02	Icahn School Med Mount Sinai	Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose
US20180085319A1 (en)	2016-09-27	2018-03-29	Takashi Kei Kishimoto	Methods and compositions for treating cancer
GB201616365D0 (en) *	2016-09-27	2016-11-09	Helsingin Yliopisto	Non-genetic modification of enveloped viruses
AU2018205496A1 (en)	2017-01-07	2019-07-25	Selecta Biosciences, Inc.	Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
JP7523909B2 (ja)	2017-03-11	2024-07-29	セレクタバイオサイエンシーズインコーポレーテッド	抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
BR112020007157A2 (pt)	2017-10-13	2020-09-24	Selecta Biosciences, Inc.	métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
US12246031B2 (en)	2018-02-13	2025-03-11	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
AU2019251421B2 (en)	2018-04-09	2025-05-01	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
EP3781689A1 (en)	2018-04-19	2021-02-24	Checkmate Pharmaceuticals, Inc.	Synthetic rig-i-like receptor agonists
WO2020018583A1 (en)	2018-07-16	2020-01-23	Selecta Biosciences, Inc.	Methods and compositions of otc constructs and vectors
WO2020018587A1 (en)	2018-07-16	2020-01-23	Selecta Biosciences, Inc.	Methods and compositions of mma constructs and vectors
CN112639077B (zh) *	2018-08-07	2023-06-20	中国科学院生物物理研究所	活化cd4+ t细胞的方法
EP3902530A4 (en) *	2018-12-28	2023-01-25	Ramot at Tel-Aviv University Ltd.	POLYMER NANOVACCINE AND USES THEREOF
CN113993523A (zh)	2019-04-17	2022-01-28	指南针探路者有限公司	用赛洛西宾治疗抑郁症和其他各种病症
JP2022531201A (ja)	2019-04-28	2022-07-06	セレクタバイオサイエンシーズインコーポレーテッド	ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法
AU2020284555A1 (en)	2019-05-28	2021-12-23	Selecta Biosciences, Inc.	Methods and compositions for attenuated anti-viral transfer vector immune response
WO2021081353A1 (en)	2019-10-23	2021-04-29	Checkmate Pharmaceuticals, Inc.	Synthetic rig-i-like receptor agonists
DE102020113731B4 (de) *	2020-05-20	2024-02-08	FiberBridge Photonics GmbH	Glasfaser und Glasfaserprodukt
JP2023530095A (ja) *	2020-06-09	2023-07-13	アイコサバックス，インコーポレイテッド	ウイルス様粒子を作製する方法
US20220133864A1 (en)	2020-11-04	2022-05-05	Selecta Biosciences, Inc.	Methods and compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en)	2021-01-05	2023-11-15	Selecta Biosciences, Inc.	Viral vector dosing protocols
KR20230171435A (ko)	2021-03-19	2023-12-20	트레인드 테라퓨틱스 디스커버리, 아이엔씨.	훈련된 면역을 조절하기 위한 화합물 및 이의 사용 방법
US20220323607A1 (en)	2021-04-09	2022-10-13	Selecta Biosciences, Inc.	Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2023064350A1 (en)	2021-10-12	2023-04-20	Selecta Biosciences, Inc.	Viral vector dosing protocols
WO2023064367A1 (en)	2021-10-12	2023-04-20	Selecta Biosciences, Inc.	Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064887A1 (en)	2021-10-15	2023-04-20	The Board Of Trustees Of The University Of Illinois	Mechanochemical dynamic therapy for focal cancer treatment
WO2023086615A1 (en)	2021-11-14	2023-05-19	Selecta Biosciences, Inc.	Multiple dosing with viral vectors
WO2023133319A1 (en)	2022-01-10	2023-07-13	Selecta Biosciences, Inc.	High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin
US20230322884A1 (en)	2022-03-09	2023-10-12	Selecta Biosciences, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en)	2022-03-09	2023-11-09	Selecta Biosciences, Inc.	Immunosuppressants in combination with anti-igm agents and related dosing
US20230372535A1 (en)	2022-03-25	2023-11-23	Selecta Biosciences, Inc.	Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en)	2022-04-08	2023-11-30	Selecta Biosciences, Inc.	High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2023242155A1 (en) *	2022-06-14	2023-12-21	Janssen Vaccines & Prevention B.V.	Compositions and methods for the diagnosis of hiv infection
JP2025526816A (ja)	2022-08-11	2025-08-15	カーティザンセラピューティクス，インコーポレーテッド	免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法
TW202424182A (zh)	2022-08-30	2024-06-16	瑞士商賽巴動物健康股份有限公司	經修飾的cmv類病毒粒子
WO2024229432A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229350A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229370A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Compositions and methods for treating gvhd
WO2024229380A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2025054423A1 (en) *	2023-09-08	2025-03-13	University Of Massachusetts	Chimeric hpv-ng compositions and methods of use thereof
WO2025186188A1 (en)	2024-03-04	2025-09-12	Boehringer Ingelheim Vetmedica Gmbh	Active vaccination for the treatment of ngf-related disorders
US20250281585A1 (en)	2024-03-06	2025-09-11	Elanco Us Inc.	Veterinary compositions of modified virus-like particles of cmv and il-1 beta mutein antigens

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3160926D1 (en)	1980-04-15	1983-10-27	Beecham Group Plc	Allergens modified with polysarcosines
US5204096A (en) *	1984-03-07	1993-04-20	New York Blood Center, Inc.	Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) *	1984-09-12	1988-02-02	Chiron Corporation	Hybrid particle immunogens
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
FR2581394B1 (fr)	1985-05-02	1988-08-05	Grp Genie Genetique	Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US5374426A (en) *	1986-09-03	1994-12-20	University Of Saskatchewan	Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5143726A (en) *	1986-12-09	1992-09-01	The Scripps Research Institute	T cell epitopes of the hepatitis B virus nucleocapsid protein
CN87100603A (zh) *	1987-01-21	1988-08-10	昂科公司	抗黑素瘤疫苗
US4918166A (en) *	1987-04-10	1990-04-17	Oxford Gene Systems Limited	Particulate hybrid HIV antigens
US5057540A (en) *	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
GB8903313D0 (en)	1989-02-14	1989-04-05	Wellcome Found	Conjugates
NZ235315A (en)	1989-09-19	1991-09-25	Wellcome Found	Chimaeric hepadnavirus core antigen proteins and their construction
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5334394A (en)	1990-06-22	1994-08-02	The Regents Of The University Of California	Human immunodeficiency virus decoy
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
GB9101550D0 (en)	1991-01-24	1991-03-06	Mastico Robert A	Antigen-presenting chimaeric protein
GB9114003D0 (en) *	1991-06-28	1991-08-14	Mastico Robert A	Chimaeric protein
ZA934199B (en)	1992-06-18	1994-01-10	Akzo Nv	Carrier system against gnrh
GB9213601D0 (en) *	1992-06-26	1992-08-12	Mastico Robert A	Protein based delivery system
RU95104940A (ru)	1992-07-27	1997-01-10	Хайбрайдон	Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
FR2695563B1 (fr) *	1992-09-11	1994-12-02	Pasteur Institut	Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
GB9227068D0 (en)	1992-12-29	1993-02-24	British Bio Technology	Novel proteinaceous particles
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US5874560A (en) *	1994-04-22	1999-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Melanoma antigens and their use in diagnostic and therapeutic methods
AU706443B2 (en)	1994-04-22	1999-06-17	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Melanoma antigens
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030050263A1 (en) *	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
CA2560114A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5935821A (en)	1995-01-17	1999-08-10	Board Of Trustees Of The University Of Kentucky	Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1996030523A2 (en)	1995-03-31	1996-10-03	Hans Wolf	Antigen presentation system based on retrovirus-like particles
US5780448A (en) *	1995-11-07	1998-07-14	Ottawa Civic Hospital Loeb Research	DNA-based vaccination of fish
CA2244946C (en)	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
EP0855184A1 (en)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
GB9702021D0 (en)	1997-01-31	1997-03-19	Imperial College	Medicaments
EP2172216A3 (en) *	1997-03-10	2010-11-24	Ottawa Hospital Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998049195A1 (en) *	1997-04-29	1998-11-05	Universiteit Utrecht	Corona virus-like particles as tools for vaccination and therapy
CA2288129A1 (en)	1997-05-01	1998-11-12	Chiron Corporation	Use of virus-like particles as adjuvants
ATE370740T1 (de)	1997-05-20	2007-09-15	Ottawa Health Research Inst	Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en)	1997-06-06	2012-05-02	The Regents of the University of California	Inhibitors of DNA immunostimulatory sequence activity
US6025470A (en)	1997-06-23	2000-02-15	Ludwig Institute For Cancer Research	Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
AU732468B2 (en) *	1997-06-23	2001-04-26	Ludwig Institute For Cancer Research	Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
FR2764826B1 (fr)	1997-06-24	1999-09-03	Tempora O	Procede de nettoyage de surface poreuse, notamment en pierre et composition adaptee
US6169175B1 (en)	1997-08-06	2001-01-02	Centers For Disease Control And Prevention	Preparation and use of recombinant influenza A virus M2 construct vaccines
PT1009413E (pt)	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US5989868A (en) *	1997-09-12	1999-11-23	The Board Of Regents Of The University Of Oklahoma	Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US6171591B1 (en)	1997-12-08	2001-01-09	Pentamer Pharmaceuticals, Inc.	Recombinant nodavirus compositions and methods
BR9907855A (pt)	1998-02-12	2001-04-24	Immune Complex Corp	Conjugado de proteìna de núcleo de hepatite b estrategicamente modificada, partìcula de proteìna, conjugado de partìculas de proteìna, conjugado de proteìna de fusão imunogênica, inóculo, e, processo para induzir anticorpos em um hospedeiro animal
CA2323929C (en)	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6541438B1 (en) *	1998-05-01	2003-04-01	The Procter & Gamble Company	Laundry detergent and/or fabric care compositions comprising a modified cellulase
US5990085A (en)	1998-05-04	1999-11-23	Michigan State University	Inhibin-HBc fusion protein
ATE305507T1 (de) *	1998-05-14	2005-10-15	Coley Pharm Gmbh	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
CZ302062B6 (cs)	1998-06-30	2010-09-22	Om Pharma	Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje
WO2000006588A1 (en)	1998-07-27	2000-02-10	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
US5962636A (en) *	1998-08-12	1999-10-05	Amgen Canada Inc.	Peptides capable of modulating inflammatory heart disease
AU777225B2 (en)	1998-09-03	2004-10-07	Coley Pharmaceutical Gmbh	G-motif oligonucleotides and uses thereof
DE69929232T2 (de)	1998-10-21	2006-08-31	The United States Government As Represented By The Department Of Health And Human Services	Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en)	1998-11-23	2002-04-30	Loyola University Of Chicago	Chimeric biotin-binding papillomavirus protein
DK1135162T3 (da)	1998-11-30	2009-01-19	Cytos Biotechnology Ag	Ordnet molekylær præsentation af allergener, fremstillingsfremgangsmåde samt anvendelse
EA004497B1 (ru)	1998-12-04	2004-04-29	Байоджен, Инк.	Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
CA2357004A1 (en)	1998-12-23	2000-06-29	Boyce Thompson Institute For Plant Research	Expression of immunogenic hepatitis b surface antigens in transgenic plants
JP2003523721A (ja) *	1998-12-31	2003-08-12	カイロンコーポレイション	抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
JP2002537403A (ja)	1999-02-25	2002-11-05	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ＩｇＥのＣ−イプシロン−３またはＣ−イプシロン−４ドメイン由来のエピトープまたはミモトープ、その拮抗薬、及びそれらの治療的使用
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
TR200103018T2 (tr)	1999-04-19	2002-02-21	Beecham Biologicals S.A. Smithkline	İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AU6801800A (en) *	1999-08-30	2001-03-26	Ludwig Institute For Cancer Research	Isolated nona and decapeptides which bind to hla molecules, and the use thereof
UA77152C2 (en)	1999-09-25	2006-11-15		Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
AU783118B2 (en) *	1999-09-27	2005-09-29	Coley Pharmaceutical Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US20010044416A1 (en) *	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
EP1975182A1 (en)	2000-02-01	2008-10-01	PanGenetics B.V.	CD40-binding APC-activating molecules
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6756044B1 (en)	2000-02-09	2004-06-29	Genvec, Inc.	Antigenic complexes and methods
CN100360556C (zh)	2000-04-07	2008-01-09	利兹创新有限公司大学	乙型肝炎核心抗原的融合蛋白
CA2407897A1 (en)	2000-05-05	2001-11-15	Cytos Biotechnology Ag	Molecular antigen arrays and vaccines
DE60117978T2 (de)	2000-06-22	2006-11-02	UCB Pharma Ltd., Slough	Modifizierung des hepatitis b kernantigens
AUPQ912000A0 (en)	2000-07-31	2000-08-24	Crown In The Right Of The Queensland Department Of Health, The	Improved virus like particles
US20030138769A1 (en)	2000-08-16	2003-07-24	Birkett Ashley J.	Immunogenic HBc chimer particles having enhanced stability
US20030055014A1 (en) *	2000-12-14	2003-03-20	Bratzler Robert L.	Inhibition of angiogenesis by nucleic acids
WO2003031466A2 (en)	2001-10-05	2003-04-17	Cytos Biotechnology Ag	Angiotensin peptide-carrier conjugates and uses thereof
US7320793B2 (en)	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
US7094409B2 (en) *	2001-01-19	2006-08-22	Cytos Biotechnology Ag	Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) *	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2003040308A2 (en)	2001-07-27	2003-05-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
EP2196217A1 (en) *	2001-09-14	2010-06-16	Cytos Biotechnology AG	Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2492823A1 (en) *	2001-09-14	2003-03-27	Martin F. Bachmann	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) *	2001-10-05	2006-10-03	Cytos Biotechnology Ag	Angiotensin peptide-carrier conjugates and uses thereof
AU2002346960A1 (en)	2001-10-06	2003-04-22	Merial Limited	Methods and compositions for promoting growth and innate immunity in young animals
ES2316628T3 (es)	2001-11-07	2009-04-16	Cytos Biotechnology Ag	Disposicion ordenada de antigenos que comprende rankl para el tratamiento de enfermedades oseas.
PL369863A1 (en)	2001-11-07	2005-05-02	Cytos Biotechnology Ag	Antigen arrays for treatment of allergic eosinophilic diseases
TW200303759A (en)	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
AU2003205623A1 (en)	2002-01-18	2003-07-30	Cytos Biotechnology Ag	Prion protein carrier-conjugates
US20030219459A1 (en) *	2002-01-18	2003-11-27	Cytos Biotechnology Ag	Prion protein carrier-conjugates
ATE489969T1 (de) *	2002-06-20	2010-12-15	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2004007538A2 (en)	2002-07-17	2004-01-22	Cytos Biotechnology Ag	Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
KR20050027168A (ko)	2002-07-19	2005-03-17	사이토스 바이오테크놀로지 아게	그렐린-캐리어 컨쥬게이트
DK1524994T3 (da)	2002-07-19	2011-08-15	Cytos Biotechnology Ag	Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays
JP4509999B2 (ja)	2003-02-17	2010-07-21	ブルクハルト，ペーター	医薬送達及び抗原提示システムとしてのペプチドナノ粒子
US20060210588A1 (en) *	2003-03-26	2006-09-21	Cytos Biotechnology Ag	Hiv-peptide-carrier-conjugates
CN100560719C (zh) *	2003-03-26	2009-11-18	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en) *	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
AU2004255470B2 (en) *	2003-07-10	2010-08-19	Cytos Biotechnology Ag	Packaged virus-like particles
WO2005014110A1 (en)	2003-07-22	2005-02-17	Cytos Biotechnology Ag	Cpg-packaged liposomes
GEP20094767B (en)	2003-10-30	2009-09-10	Coley Pharm Group Inc	C-class oligonucleotide analogs with enhanced immunostimulatory potency
MX2007003171A (es) *	2004-09-21	2007-05-23	Cytos Biotechnology Ag	Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
JP5484732B2 (ja) *	2005-12-14	2014-05-07	サイトスバイオテクノロジーアーゲー	過敏症の治療のための免疫賦活性核酸パッケージ粒子

2004
- 2004-03-25 CN CNB2004800079060A patent/CN100560719C/zh not_active Expired - Fee Related
- 2004-03-25 CA CA002519165A patent/CA2519165A1/en not_active Abandoned
- 2004-03-25 WO PCT/EP2004/003165 patent/WO2004084940A1/en not_active Ceased
- 2004-03-25 WO PCT/EP2004/003163 patent/WO2004084939A2/en not_active Ceased
- 2004-03-25 EP EP04723203A patent/EP1606398A1/en not_active Withdrawn
- 2004-03-25 CA CA002517839A patent/CA2517839A1/en not_active Abandoned
- 2004-03-25 AU AU2004224761A patent/AU2004224761A1/en not_active Abandoned
- 2004-03-25 AU AU2004224762A patent/AU2004224762B2/en not_active Expired
- 2004-03-25 EP EP04723207A patent/EP1605973B1/en not_active Expired - Lifetime
- 2004-03-25 NZ NZ542323A patent/NZ542323A/en unknown
- 2004-03-25 ZA ZA200507063A patent/ZA200507063B/en unknown
- 2004-03-25 US US10/550,518 patent/US7517520B2/en not_active Expired - Lifetime
- 2004-03-25 ZA ZA200507562A patent/ZA200507562B/en unknown
- 2004-03-25 MX MXPA05009289A patent/MXPA05009289A/es active IP Right Grant
- 2004-03-25 BR BRPI0408623-6A patent/BRPI0408623A/pt not_active IP Right Cessation
- 2004-03-25 JP JP2006504862A patent/JP5022028B2/ja not_active Expired - Fee Related
- 2004-03-25 KR KR1020057017197A patent/KR20050115913A/ko not_active Ceased
- 2004-03-25 EP EP04723204A patent/EP1605972A2/en not_active Withdrawn
- 2004-03-25 WO PCT/EP2004/003164 patent/WO2004085635A1/en not_active Ceased
- 2004-03-25 CA CA002517675A patent/CA2517675A1/en not_active Abandoned
- 2004-03-25 CN CN200910175527A patent/CN101675993A/zh active Pending
- 2004-03-25 RU RU2005129727/13A patent/RU2351362C2/ru not_active IP Right Cessation
- 2004-03-25 AU AU2004223736A patent/AU2004223736B2/en not_active Ceased
2005
- 2005-08-16 ZA ZA200506541A patent/ZA200506541B/en unknown
2009
- 2009-03-24 US US12/410,085 patent/US20100098722A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100098722A1 (en)	2010-04-22
CA2519165A1 (en)	2004-10-07
AU2004224762A1 (en)	2004-10-07
CA2517839A1 (en)	2004-10-07
CN101675993A (zh)	2010-03-24
EP1605973B1 (en)	2012-09-26
JP5022028B2 (ja)	2012-09-12
WO2004084939A8 (en)	2005-06-09
BRPI0408623A (pt)	2006-03-07
MXPA05009289A (es)	2005-10-18
EP1606398A1 (en)	2005-12-21
ZA200506541B (en)	2006-12-27
EP1605973A1 (en)	2005-12-21
US7517520B2 (en)	2009-04-14
CN1764719A (zh)	2006-04-26
WO2004084939A2 (en)	2004-10-07
US20060251677A1 (en)	2006-11-09
KR20050115913A (ko)	2005-12-08
AU2004224761A1 (en)	2004-10-07
WO2004084939A3 (en)	2005-03-31
EP1605972A2 (en)	2005-12-21
RU2351362C2 (ru)	2009-04-10
RU2005129727A (ru)	2006-03-20
AU2004223736A1 (en)	2004-10-07
WO2004085635A1 (en)	2004-10-07
JP2006523189A (ja)	2006-10-12
CA2517675A1 (en)	2004-10-07
ZA200507063B (en)	2007-03-28
WO2004084940A1 (en)	2004-10-07
NZ542323A (en)	2008-07-31
CN100560719C (zh)	2009-11-18
AU2004224762B2 (en)	2009-12-24
AU2004223736B2 (en)	2010-05-27